GenSight Biologics announces the availability of a prospectus in connection with the listing of new shares on Euronext Paris

GenSight Biologics announces a successful offering for an amount of approximately €4.7 million

GenSight Biologics announces launch of an offering for an indicative amount of €5 million that has received subscription commitments from new and existing shareholders totaling €4 million

GenSight Biologics Reports Cash Position as of September 30, 2023, and Provides Business Update

GenSight Biologics Reports Interim Financial Results for the First Half of 2023

GenSight Biologics obtains funding of €10 million from Sofinnova Partners, Invus and UPMC Enterprises

GenSight Biologics Provides Financial and Operational Update

Annual General Meeting on June 21, 2023

GenSight Biologics Announces the Filing of its 2022 Universal Registration Document and Reschedules its Annual General Meeting on June 21, 2023

GenSight Biologics Reports Cash Position as of March 31, 2023, and Provides Business Update